Phathom Pharmaceuticals Q4 revenue slightly beats expectations

Overview

• Biopharmaceutical firm's Q4 revenue slightly beat analyst expectations

• Company reduced Q4 net loss compared to previous year

• Strengthened financial position through $130 mln equity offering and debt modification

Outlook

• Phathom expects operating profitability beginning in Q3 2026

• Company forecasts FY 2026 net revenues of $320–$345 mln

• Phathom anticipates gross margin of approximately 80% for FY 2026

Result Drivers

• VOQUEZNA PRESCRIPTIONS - Q4 saw a 24% increase in VOQUEZNA prescriptions, driving revenue growth

• SALES FORCE REALIGNMENT - Phathom completed sales force realignment, strengthening sales team and marketing initiatives

• EXPENSE DISCIPLINE - Decrease in Q4 operating expenses due to reduced promotional and personnel costs

Company press release: ID:nGNX8rk2FB

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $24.00, about 94.8% above its February 25 closing price of $12.32

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)